NYSE American - Delayed Quote USD

IGC Pharma, Inc. (IGC)

Compare
0.3450
+0.0137
+(4.12%)
At close: January 10 at 3:57:44 PM EST
0.3450
0.00
(0.00%)
After hours: 7:57:26 PM EST
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for IGC

Recent News: IGC

View More

IGC Pharma Names IGC-AD1 Phase 2 Clinical Trial for Alzheimer's Agitation "CALMA" and Expands Recruitment Strategy
ACCESSWIRE 2 days ago

IGC Pharma Announces Participation in BioPartnering at JPM Alongside the J.P. Morgan 43rd Annual Healthcare Conference 2025
ACCESSWIRE 22 days ago

IGC Pharma Advances IGC-AD1 as a Potential Alzheimer's Therapy Addressing Cognitive Impairment and Underlying Disease Pathology
ACCESSWIRE last month
IGC Pharma Announces Additional Phase 2 Interim Results Highlighting Cognitive Benefits of IGC-AD1 for Alzheimer's Treatment

IGC Pharma Announces Additional Phase 2 Interim Results Highlighting Cognitive Benefits of IGC-AD1 for Alzheimer's Treatment
Business Wire last month
IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasing Progress in Its Alzheimer’s Pipeline

IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasing Progress in Its Alzheimer’s Pipeline
ACCESSWIRE last month

IGC Pharma Announces Publication of IMS Spotlight Interview Highlighting Strategic Expansion in Alzheimer’s and Weight Loss Therapies
ACCESSWIRE 2 months ago

IGC Pharma Announces Patient Enrollment at Toronto's Baycrest in Phase 2 Trial Investigating IGC-AD1
ACCESSWIRE 2 months ago
IGC Pharma Wins 2 Prizes in Phase 1 of National Institutes of Health's AI PREPARE Challenge

IGC Pharma Wins 2 Prizes in Phase 1 of National Institutes of Health's AI PREPARE Challenge
ACCESSWIRE 3 months ago
IGC Pharma Announces Additional Data Supporting IGC-AD1 as an Alzheimer's Treatment

IGC Pharma Announces Additional Data Supporting IGC-AD1 as an Alzheimer's Treatment
Business Wire 3 months ago
IGC Pharma Advances IGC-AD1 Toward Clinical Trials as a Potential anti-Amyloid Plaque Treatment for Alzheimer's Disease

IGC Pharma Advances IGC-AD1 Toward Clinical Trials as a Potential anti-Amyloid Plaque Treatment for Alzheimer's Disease
Business Wire 4 months ago
IGC Announces Results of its 2024 Annual Stockholders Meeting

IGC Announces Results of its 2024 Annual Stockholders Meeting
Business Wire 4 months ago
View More

Related Tickers

OGEN Oragenics, Inc.
0.3430
+2.82%
 
APTO Aptose Biosciences Inc.
0.2200
+3.19%
 
INAB IN8bio, Inc.
0.3233
+3.42%
 
LYRA Lyra Therapeutics, Inc.
0.1955
-2.59%
 
CYCC Cyclacel Pharmaceuticals, Inc.
0.4199
+1.21%
 
VINC Vincerx Pharma, Inc.
0.1901
-1.50%
 
VTVT vTv Therapeutics Inc.
13.80
-2.06%
 
SPRB Spruce Biosciences, Inc.
0.3700
-2.63%
 
AIM AIM ImmunoTech Inc.
0.2150
-0.92%
 
VIRX Viracta Therapeutics, Inc.
0.1860
-0.91%